Particularly Systemic Lupus Erythematosus

Oral brepocitinib failed to meet its primary endpoint in a phase 2 trial of adults with moderate to severe lupus, according to a press release from the manufacturer.

Vera Therapeutics Inc. announced new data for its product candidate atacicept in two presentations at the European Renal Association Congress in France.